|
EP0170269A3
(en)
|
1984-08-02 |
1987-09-23 |
Kao Corporation |
Medicated cosmetic compositions
|
|
US5358866A
(en)
|
1991-07-03 |
1994-10-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cytosine deaminase negative selection system for gene transfer techniques and therapies
|
|
US5801029A
(en)
|
1993-02-16 |
1998-09-01 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
|
BR9405507A
(pt)
|
1993-07-13 |
1999-05-25 |
Rhone Poulenc Rorer Sa |
Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
|
|
US5631236A
(en)
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
|
US5595756A
(en)
*
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5830686A
(en)
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
|
US5677170A
(en)
|
1994-03-02 |
1997-10-14 |
The Johns Hopkins University |
In vitro transposition of artificial transposons
|
|
US5587299A
(en)
|
1994-04-20 |
1996-12-24 |
Memorial Sloan-Kettering Cancer Center |
Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof
|
|
US5877011A
(en)
|
1996-11-20 |
1999-03-02 |
Genzyme Corporation |
Chimeric adenoviral vectors
|
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
|
CN1242051A
(zh)
|
1996-12-31 |
2000-01-19 |
昂尼克斯药物公司 |
用于肿瘤治疗和预防的致细胞病变病毒
|
|
DE69838510T2
(de)
|
1997-02-20 |
2008-07-03 |
Johns Hopkins University School Of Medicine |
Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren
|
|
AU9603898A
(en)
|
1997-10-09 |
1999-05-03 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
US20030044384A1
(en)
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
US6291214B1
(en)
|
1998-05-11 |
2001-09-18 |
Glaxo Wellcome Inc. |
System for generating recombinant viruses
|
|
US20020019051A1
(en)
|
1998-05-27 |
2002-02-14 |
Monika Lusky |
Chimeric adenoviral vectors
|
|
US20030017138A1
(en)
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
|
CN1110553C
(zh)
|
1998-07-15 |
2003-06-04 |
杭州赛狮生物技术开发有限公司 |
基因工程腺病毒及其用途
|
|
AU767975B2
(en)
|
1998-09-11 |
2003-11-27 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
|
JP4409097B2
(ja)
|
1998-12-09 |
2010-02-03 |
アメリカ合衆国 |
複数の共刺激分子を発現する組換えベクターおよびその利用
|
|
DE60029195T2
(de)
|
1999-02-22 |
2007-06-28 |
Transgene S.A. |
Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
|
|
PL351553A1
(en)
|
1999-04-09 |
2003-05-05 |
Aventis Pharma Sa |
Composition intended to preserve contagious adenoviruses of recombination type
|
|
PT1816205E
(pt)
|
1999-05-17 |
2011-11-15 |
Crucell Holland Bv |
Adenovírus recombinante baseado no serótipo 48 (ad48)
|
|
ATE291633T1
(de)
|
1999-06-01 |
2005-04-15 |
Univ Washington |
Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
|
|
JP4827353B2
(ja)
|
1999-08-09 |
2011-11-30 |
ターゲティッド ジェネティクス コーポレイション |
鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
|
|
US7396679B2
(en)
|
1999-11-15 |
2008-07-08 |
Onyx Pharmaceuticals, Inc. |
Oncolytic adenovirus
|
|
AU2695101A
(en)
|
2000-01-21 |
2001-07-31 |
Biovex Ltd |
Virus strains
|
|
US7456009B2
(en)
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
EP1301612A2
(en)
|
2000-05-31 |
2003-04-16 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
|
JP2004500863A
(ja)
|
2000-06-06 |
2004-01-15 |
ブリストル−マイヤーズ スクイブ カンパニー |
免疫調節に有用なｂ７関連核酸およびポリペプチド
|
|
WO2002053759A1
(en)
|
2001-01-04 |
2002-07-11 |
Wadell Goeran |
Viral vector for gene therapy
|
|
US20050175589A1
(en)
|
2001-07-13 |
2005-08-11 |
Btg International Limited |
Anti-neoplastic viral agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
EP1327688A1
(en)
|
2002-01-14 |
2003-07-16 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Adenoviruses with enhanced lytic potency
|
|
CA2474777A1
(en)
|
2002-02-01 |
2003-08-07 |
Transgene S.A. |
Adenoviral vectors for modulating the cellular activities associated with pods
|
|
AU2003223775A1
(en)
|
2002-04-30 |
2003-11-17 |
Duke University |
Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
|
|
US20040167088A1
(en)
|
2003-02-25 |
2004-08-26 |
Genvec, Inc. |
Method of using adenoviral vectors with increased persistence in vivo
|
|
WO2004087930A1
(en)
|
2003-03-28 |
2004-10-14 |
Saint Louis University |
Adenovirus replication-competent vectors expressing trail
|
|
US20050136035A1
(en)
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
|
EP1646717A4
(en)
|
2003-07-18 |
2006-12-20 |
Onyx Pharma Inc |
ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES
|
|
KR20120125634A
(ko)
|
2003-10-16 |
2012-11-16 |
마이크로메트 에이지 |
다중특이적 탈면역화된 ｃｄ3-바인더
|
|
WO2005086922A2
(en)
|
2004-03-10 |
2005-09-22 |
Board Of Regents, University Of Texas System |
Oncolytic adenovirus armed with therapeutic genes
|
|
US20080292592A1
(en)
|
2004-04-30 |
2008-11-27 |
Sunil Chada |
Oncolytic Adenovirus Armed with Therapeutic Genes
|
|
ATE491799T1
(de)
|
2004-05-26 |
2011-01-15 |
Bayer Schering Pharma Ag |
Chimäre adenoviren zur verwendung in der krebsbehandlung
|
|
US20060292682A1
(en)
|
2004-07-22 |
2006-12-28 |
Hawkins Lynda K |
Addition of transgenes into adenoviral vectors
|
|
JP2008511336A
(ja)
|
2004-09-01 |
2008-04-17 |
アメリカ合衆国 |
免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
|
|
US7550296B2
(en)
|
2004-12-01 |
2009-06-23 |
Bayer Schering Pharma Ag |
Generation of replication competent viruses for therapeutic use
|
|
US8765146B2
(en)
|
2005-08-31 |
2014-07-01 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
|
DE102005055128B4
(de)
|
2005-11-15 |
2015-04-02 |
Universität Rostock |
Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
|
|
ES2304281B1
(es)
|
2006-02-01 |
2009-08-12 |
Dnatrix Inc. |
Adenovirus oncoliticos para el tratamiento del cancer.
|
|
JP5448840B2
(ja)
|
2006-12-22 |
2014-03-19 |
プシオクサス・セラピューティクス・リミテッド |
腫瘍退縮アデノウイルスの作出およびその使用
|
|
WO2009097443A2
(en)
|
2008-01-29 |
2009-08-06 |
Remedy Pharmaceuticals, Inc. |
Liquid formulations of compounds active at sulfonylurea receptors
|
|
CN102695520A
(zh)
|
2008-05-27 |
2012-09-26 |
昂科利蒂克斯生物科技公司 |
调节间隙压力与溶瘤病毒的递送和分布
|
|
US20120034228A1
(en)
|
2008-10-01 |
2012-02-09 |
Micromet Ag |
CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
|
|
CN101381742A
(zh)
|
2008-10-23 |
2009-03-11 |
浙江理工大学 |
晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
|
|
ES2385251B1
(es)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
CA2776037A1
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
|
WO2011043719A1
(en)
|
2009-10-05 |
2011-04-14 |
Ya-Fang Mei |
Replicating viral vectors for gene therapy
|
|
JP5981916B2
(ja)
|
2010-08-16 |
2016-09-07 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
アデノウイルスの構築方法
|
|
CN103221544A
(zh)
|
2010-09-24 |
2013-07-24 |
昂克斯治疗有限公司 |
编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体
|
|
ES2857734T3
(es)
*
|
2011-08-23 |
2021-09-29 |
Roche Glycart Ag |
Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
|
|
US20140316369A1
(en)
|
2011-11-14 |
2014-10-23 |
Regenerative Sciences, Llc |
Suspended particle delivery systems and methods
|
|
CN102586327B
(zh)
|
2012-01-18 |
2013-09-11 |
陕西师范大学 |
一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
|
|
SG11201406592QA
(en)
|
2012-05-04 |
2014-11-27 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
JP2016512199A
(ja)
|
2013-03-05 |
2016-04-25 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
腫瘍溶解性ウイルス
|
|
GB201322851D0
(en)
*
|
2013-12-23 |
2014-02-12 |
Psioxus Therapeutics Ltd |
Method
|
|
GB2519564A
(en)
|
2013-10-24 |
2015-04-29 |
Shared Band Ltd |
Multicast transmission over bonded broadband
|
|
GB201318793D0
(en)
|
2013-10-24 |
2013-12-11 |
Plaquetec Ltd |
Vascular Biomarkers
|
|
EP3831398A1
(en)
|
2013-10-25 |
2021-06-09 |
PsiOxus Therapeutics Limited |
Oncolytic adenoviruses armed with heterologous genes
|
|
CA2931322A1
(en)
|
2013-11-22 |
2015-05-28 |
Dnatrix, Inc. |
Adenovirus expressing immune cell stimulatory receptor agonist(s)
|
|
WO2015153912A1
(en)
|
2014-04-03 |
2015-10-08 |
Igm Biosciences, Inc. |
Modified j-chain
|
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
SG11201701502VA
(en)
|
2014-08-27 |
2017-03-30 |
Psioxus Therapeutics Ltd |
A process for the production of adenovirus
|
|
GB201503500D0
(en)
|
2015-03-02 |
2015-04-15 |
Ucl Business Plc |
Cell
|
|
CN107406859A
(zh)
|
2015-03-17 |
2017-11-28 |
倾斜生物医疗公司 |
编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途
|
|
KR20180118249A
(ko)
|
2015-04-30 |
2018-10-30 |
싸이오서스 테라퓨틱스 엘티디. |
B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스
|
|
AU2016369485B2
(en)
|
2015-12-17 |
2024-02-01 |
Akamis Bio Limited |
Group B adenovirus encoding an anti-TCR-complex antibody or fragment
|
|
EP3430148A4
(en)
|
2016-03-18 |
2020-01-01 |
Nantcell, Inc. |
MULTIMODAL VECTOR FOR DENDRITIC CELL INFECTION
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
CA3033267A1
(en)
|
2016-08-29 |
2018-03-08 |
Psioxus Therapeutics Limited |
Adenovirus armed with bispecific t cell engager (bite)
|
|
EP3872180A1
(en)
|
2016-10-20 |
2021-09-01 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
WO2018083259A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
GB201801614D0
(en)
|
2018-01-31 |
2018-03-14 |
Psioxus Therapeutics Ltd |
Formulation
|